EYEN - Eyenovia Inc
IEX Last Trade
0.5518
0.017 3.008%
Share volume: 3,063,583
Last Updated: Fri 30 Aug 2024 09:59:35 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$0.54
0.02
3.10%
Fundamental analysis
25%
Profitability
25%
Dept financing
5%
Liquidity
50%
Performance
23%
Performance
5 Days
-5.48%
1 Month
-61.26%
3 Months
-22.74%
6 Months
-76.08%
1 Year
-71.50%
2 Year
-66.04%
Key data
Stock price
$0.55
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.37 - $2.57
52 WEEK CHANGE
-$0.72
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO:
Region: US
Website: eyenoviabio.com
Employees: 44
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: eyenoviabio.com
Employees: 44
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
eyenovia, inc. (nasdaq: eyen) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.
Recent news